Table.

Effect on tumor angiogenesis of cell enrichment with WT tumor gangliosides

Cells	WT		P	DKO		P
WT Gangliosides	−	+		−	+
Tumor vessels
H&E	3.8±1.7	4.2 ±3.9	N.S.	0.4 ±0.6	3.6 ±2.8	<0.0001
CD31	12.9±2.7	12.8 ±3.1	N.S.	0.1 ±0.3	8.0 ±5.2	<0.0001

10⁵ WT or DKO cells were injected s.c. with or without 100 pmol WT tumor gangliosides, as in Fig. 3. Tumors were harvested and analyzed on days 7–9, except for DKO alone tumors (day 14). Vessels ≥100 µm long/0.22mm² field were quantified (mean ± SD, 3 mice/group, 5–8 fields/tumor). N.S. = not significant. Other comparisons: WT vs. DKO (H&E or CD31), P<0.0001; WT vs. DKO + G (H&E), N.S; WT vs. DKO + G (CD31), p<0.01.